Evidence map›Paper›PMID 37193964›Full record

ArticleBMC bioinformatics2023

Drug repurposing and prediction of multiple interaction types via graph embedding.

E Amiri Souri, A Chenoweth, S N Karagiannis, S Tsoka

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Pan-cancer analysis and oncogenic implications ofJournal of cell communication and signaling · 2025
    Article
  7. Article
  8. Applications of Artificial Intelligence in Drug Repurposing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

E Amiri SouriDepartment of Informatics, Faculty of Natural, Mathematical and Engineering Sciences, King's College London, Bush House, London, WC2B 4BG, UK.
A ChenowethSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, Guy's Hospital, King's College London, London, SE1 9RT, UK.
S N KaragiannisSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, Guy's Hospital, King's College London, London, SE1 9RT, UK.
S TsokaDepartment of Informatics, Faculty of Natural, Mathematical and Engineering Sciences, King's College London, Bush House, London, WC2B 4BG, UK. sophia.tsoka@kcl.ac.uk.
King's College London · GB

Funding

Breast Cancer Now 147; KCL-BCN-Q3Cancer Research UK C30122/A11527Cancer Research UK C30122/A15774Medical Research Council MR/L023091/1
6 · The paper itself

Abstract

backgroundFinding drugs that can interact with a specific target to induce a desired therapeutic outcome is key deliverable in drug discovery for targeted treatment. Therefore, both identifying new drug-target links, as well as delineating the type of drug interaction, are important in drug repurposing studies.

resultsA computational drug repurposing approach was proposed to predict novel drug-target interactions (DTIs), as well as to predict the type of interaction induced. The methodology is based on mining a heterogeneous graph that integrates drug-drug and protein-protein similarity networks, together with verified drug-disease and protein-disease associations. In order to extract appropriate features, the three-layer heterogeneous graph was mapped to low dimensional vectors using node embedding principles. The DTI prediction problem was formulated as a multi-label, multi-class classification task, aiming to determine drug modes of action. DTIs were defined by concatenating pairs of drug and target vectors extracted from graph embedding, which were used as input to classification via gradient boosted trees, where a model is trained to predict the type of interaction. After validating the prediction ability of DT2Vec+, a comprehensive analysis of all unknown DTIs was conducted to predict the degree and type of interaction. Finally, the model was applied to propose potential approved drugs to target cancer-specific biomarkers.

conclusionDT2Vec+ showed promising results in predicting type of DTI, which was achieved via integrating and mapping triplet drug-target-disease association graphs into low-dimensional dense vectors. To our knowledge, this is the first approach that addresses prediction between drugs and targets across six interaction types.

Indexed as

Drug DiscoveryDrug RepositioningDrug InteractionsKnowledgeProteinsProteinsDrug discoveryDrug repurposingDrug-target interactionMachine learningNetwork embedding

Identifiers

PMID37193964
PMCPMC10190044
OpenAlexW4376870972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.